Business Description
Actinogen Medical Ltd
ISIN : AU000000ACW3
Description
Actinogen Medical Ltd is a biotechnology company. The company develops a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated cortisol in the brain. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 29.29 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year FCF Growth Rate | 15.7 | |||||
3-Year Book Growth Rate | -18.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -27.69 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 0.33 | |||||
9-Day RSI | 2.56 | |||||
14-Day RSI | 5.7 | |||||
3-1 Month Momentum % | -98 | |||||
6-1 Month Momentum % | -98 | |||||
12-1 Month Momentum % | -96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.19 | |||||
Quick Ratio | 4.19 | |||||
Cash Ratio | 3.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -18.8 | |||||
Shareholder Yield % | -1.49 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -106.03 | |||||
ROA % | -88.79 | |||||
ROIC % | -778.97 | |||||
3-Year ROIIC % | 2223.48 | |||||
ROC (Joel Greenblatt) % | -5297.51 | |||||
ROCE % | -103.83 | |||||
Moat Score | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 10.67 | |||||
EV-to-EBIT | -6.35 | |||||
EV-to-EBITDA | -6.51 | |||||
EV-to-Forward-EBITDA | -3.44 | |||||
EV-to-Forward-Revenue | 11.15 | |||||
EV-to-FCF | -6.85 | |||||
Earnings Yield (Greenblatt) % | -15.75 | |||||
FCF Yield % | -13.83 |
GF Value™
Actinogen Medical Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Actinogen Medical Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Guru Commentaries on OTCPK:ATGGF
No articles.
Press Release
Articles on Actinogen Medical Ltd
No articles.